HOWL Stock Analysis: Buy, Sell, or Hold?
HOWL - Werewolf Therapeutics, Inc. Common Stock
$0.87
0.44 (102.57%)
▲
5d:
+115.84%
30d:
+142.5%
90d:
+106.79%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When HOWL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: HOWL is 74.7% above its trading range ($0.50). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: HOWL is 74.7% above its trading range ($0.50). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: HOWL is currently trading at $0.87, which is considered extended relative to its 30-day fair value range of $0.32 to $0.50.
Technical Outlook: Technically, HOWL is in a strong downtrend. Immediate support is located at $0.36, while resistance sits at $1.05. The stock is showing strong short-term momentum, up 102.6% recently.
Market Sentiment: HOWL scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+701.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HOWL is in a strong downtrend. Immediate support is located at $0.36, while resistance sits at $1.05. The stock is showing strong short-term momentum, up 102.6% recently.
Market Sentiment: HOWL scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+701.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.32 -
$0.50
Company Quality Score
36/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
15.8%
All Signals
- BEARISH: Price significantly overextended (+74.7% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: Strong upward momentum (+102.6%)
- BULLISH: Trading 701.4% below Wall St target ($7.00)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.32 -
$0.50
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.36
Resistance Level
$1.05
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.55
Wall Street Target
$7.00
(+701.4%)
Revenue Growth (YoY)
-100.0%
Profit Margin
-164.8%
Share & Embed Analysis
Last updated: August 22, 2026 11:53 PM ET
Data refreshes hourly during market hours. Next update: 12:53 AM
Data refreshes hourly during market hours. Next update: 12:53 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HOWL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$109 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 40 SELL |
